FDA Approves Blueprint Medicines ' Ayvakit (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis

First precision therapy that specifically targets the primary driver of the disease Durable clinical responses, including complete remissions, shown in patients with or without prior treatment Full approval supported by robust efficacy and...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news